# Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension

> **NCT07297797** · PHASE2 · RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 234 (estimated)

## Conditions studied

- Mild to Moderate Hypertension

## Interventions

- **DRUG:** HRS-9563 Injection
- **DRUG:** sodium chloride injection

## Key facts

- **NCT ID:** NCT07297797
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-14
- **Primary completion:** 2026-07
- **Final completion:** 2027-10
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07297797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07297797, "Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07297797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*